Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Inflammatory Breast Neoplasms 1Carcinoma, Ductal, Breast 1

Interventions

Cyclophosphamide 38Paclitaxel 22Epirubicin 21Trastuzumab 20Docetaxel 20Doxorubicin 19Carboplatin 15Radiotherapy 13Taxes 11Filgrastim 11Neoadjuvant Therapy 9Bevacizumab 9Fluorouracil 8pembrolizumab 7Tamoxifen 7Albumin-Bound Paclitaxel 7Capecitabine 6pertuzumab 5Thiotepa 5Peripheral Blood Stem Cell Transplantation 5Lapatinib 5130-nm albumin-bound paclitaxel 5pegfilgrastim 4Granulocyte Colony-Stimulating Factor 4Cisplatin 4Chemotherapy, Adjuvant 4Biopsy 4tipifarnib 3eribulin 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Inflammatory Breast Neoplasms × ferric carboxymaltose × Breast × Clear all
NCT02125344 2017-07-13

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

GBG Forschungs GmbH

Phase 3 Completed
961 enrolled
Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡